589959
Amyloid A4 protein C31 chain (ABPP, APPI, APP C31)
Size
£767.00
- SKU:
- 589959
- Purity:
- Purified by Protein A affinity chromatography.
- Storage Conditions:
- -20°C
- Supplier:
- United States Biological
- Host:
- Rabbit
- Immunogen:
- Synthetic peptide corresponding to human APP at C-terminal.
- Format:
- Supplied as a liquid in PBS, 0.09% sodium azide.
- Extra Details:
- Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized by the senile plaques, neurofibrillary tangles and loss of synapses and neurons. AD has been largely viewed as a disease of toxicity being mediated by the accumulation of the amyloid beta (ABeta) peptide as plaques within the brain resulting in damage to brain cells from the binding of damaging metals, reactive oxygen species production and direct damage to cellular membranes. Recent research has suggested that the ABeta peptide is a multifunctional peptide with non-pathological effects and that its association with AD is in conjunction with its roles in combination with other proteins such as the amyloid precursor protein (APP) resulting in the imbalance between the processes of memory formation and normal forgetting. It is through the interactions of the ABeta peptide with APP that the ABeta peptide itself can affect normal modulation and signaling of APP resulting in its indicated role in the pathogenesis of AD via signaling effects rather than chemical or physical effects. There are three major APP isoforms (APP695, APP751 and APP770) that are formed through alternative splicing of precursor mRNA. APP770 represents the canonical sequence. The APP695 isoform is preferentially expressed in the central nervous system, while APP770 and APP751 are more highly expressed in peripheral tissues. It has been demonstrated that the full length APP695 can be cleaved via caspase at an intracellular site (Asp664) resulting in the release of a 31aa C-terminal peptide (C31) from the remaining larger neo-APP fragment (APP ΔC31) with both of these entities being pro-apoptotic. Immunohistochemical analysis of human brain tissue demonstrated that this cytoplasmic cleavage occurs 4-fold greater in patients with AD versus normal patients and that these cleavage products are localized to plaques and tangles in key areas of the brain affected by the disease. A single genetic mutation of aspartic acid residue 664 to alanine of APP695 led to the complete blockage of the C-terminal cleavage in vivo reversing many characteristics of the AD phenotype in a transgenic mouse model. Additionally, in cell culture it has been suggested that the neurotoxicity of Abeta is dependent on the cleavage of APP at Asp664 and the resulting Abeta -facilitated APP multimerization. Applications: Suitable for use in ELISA, Western Blot and Immunoprecipitation. Other applications not tested. Recommended Dilutions: Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
- Shipping Conditions:
- Blue Ice